8 results
Summary of dosing recommendations in renal impairment of commonly used hypoglycaemic agents

#Diabetes #Diabetic #Medications #Pharmacology #Dosing
Summary of dosing ... #Diabetic #Medications ... #Pharmacology # ... Renal #Impairment #CKD ... #Table #GFR #Hypoglycemics
Diabetes Medications Summary Table
Insulin
Lifestyle modifications
Metformin
Sulfonylureas
GLP-1 receptor agonists - ↓ major adverse CV events
TZDs
DPP-4 inhibitors
SGLT2 inhibitors -
Diabetes Medications ... Summary Table ... Improved outcomes in CKD ... #medications #table ... comparison #management #endocrinology
Sulfonylureas - Pharmacology Summary
Mechanisms of Action: Binds to the ATP-sensitive potassium channel in pancreatic beta cells,
Sulfonylureas - Pharmacology ... Summary Mechanisms ... contraindicated in CKD ... #Summary #DM2 # ... diabetes #endocrinology
Estimating the Total Daily Dose (TDD) of Insulin: Weight-Based Dosing
TDD in units of insulin = N
: Weight-Based Dosing ... (stage IV or V CKD ... #TDD #Insulin #dosing ... Weight #Based #pharmacology ... #endocrinology
DPP-4 Inhibitors - Pharmacology Summary
Mechanisms of Action: Inhibits DPP-4 (dipeptidyl peptidase 4), which normally inactivates GLP-1
4 Inhibitors - Pharmacology ... Summary Mechanisms ... DPP4 #Inhibitors #Pharmacology ... #Summary #DM2 # ... diabetes #endocrinology
NSAID Dosing in CKD
 • Carboxylic Acids: Salsalate, Choline Mg trisalicylate
 • Acetic Acids: Indomethacin, Tolmetin,
NSAID Dosing in ... CKD • Carboxylic ... trisalicylate • Acetic ... #CKD #pharmacology ... #table
GLP-1 Receptor Agonists - Pharmacology Summary
Mechanisms of Action: Stimulate glucose-dependent insulin release from the pancreas (GLP-1
Receptor Agonists - Pharmacology ... Summary Mechanisms ... Ozempic), or daily tablet ... #Summary #DM2 # ... diabetes #endocrinology
Rybelsus (oral semaglutide) - First Oral GLP-1 Agonist
Dosing:
3 mg daily x 30 days, then 7 mg
GLP-1 Agonist Dosing ... drug to remain stable ... #semaglutide #Diabetes ... #Pharmacology # ... Endocrinology